Literature DB >> 24950847

Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

Amanda Jagdis1, Peter Vadas2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24950847     DOI： 10.1016/j.anai.2014.05.001

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  6 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  Mast Cell Activation Syndrome.

Authors:  Marianne Frieri
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

3.  Mast cell disorders: Protean manifestations and treatment responses.

Authors:  Meng Chen; Alexander Kim; Bruce Zuraw; Taylor A Doherty; Sandra Christiansen
Journal:  Ann Allergy Asthma Immunol       Date:  2018-03-28       Impact factor: 6.347

4.  Efficacy of Omalizumab in Indolent Systemic Mastocytosis.

Authors:  Calum Slapnicar; Martina Trinkaus; Lisa Hicks; Peter Vadas
Journal:  Case Rep Hematol       Date:  2019-09-16

5.  Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab.

Authors:  Renee Berry; Peter Hollingsworth; Michaela Lucas
Journal:  Clin Transl Immunology       Date:  2019-09-30

Review 6.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.